发表文献2009

Calpain inhibitor SNJ-1945 attenuates events prior to angiogenesis in cultured human retinal endothelial cells.

  • Ma H, Tochigi A, Shearer TR, Azuma M.
    Department of Integrative Biosciences, Oregon Health and Science University,
  • J Ocul Pharmacol Ther. 2009 Oct;25(5):409-14.

Effect of dosing interval on the efficacy of topical ophthalmic gatifloxacin against Enterococcus faecalis in an in vitro pharmacokinetic model simulating the local eye compartment

  • Kozai S, Wada T, Kida T, Tajika T, Sakaki H, Ohtori A.
  • International Journal of Antimicrobial Agents:34,561-5,2009.

POST-MARKETING SURVEILLANCE OF ACETYLCYSTEINE ORAL SOLUTION 17.6%"SENJU®" FOR THE ANTIDOTE TO ACETAMINOPHEN OVERDOSE―Use-Results Surveillance―

  • Toshihide Suenobu*1, Toshiharu Yoshioka*2, Shinichi Maruta*1, Hidemi Shimoji*1
    *1 Senju Pharmaceutical Co.,Ltd., *2 Osaka General Medical Center
  • The Japanese Journal of Clinical Toxicology. 2006(4):383-39

POST-MARKETING SURVEILLANCE ON EFFICACY AND SAFETY OF PIMARICIN OTIC SUSPENSION (MIMIENA®)

  • Toshihide Suenobu*1, Hidemi Shimoji*1, Masakatsu Sato*2
    *1 Senju Pharmaceutical Co.,Ltd., *2 Sato Veterinary Clinic
  • Jap J Vet Dermatol. 2005(4):177-187

POST-MARKETING SURVEILLANCE OF 0.1% PRANOPROFEN OPHTHALMIC SOLUTION (TEAROSE®)

  • Mitsuharu Ota*1, Takashi Noma*1, Mayumi Morisaki*2
    *1 Ota Veterinary Hospital, *2 Senju Pharmaceutical Co.,Ltd.
  • J Vet Med. 2008(12):1001-1009

POST-MARKETING SURVEILLANCE OF GATIFLOXACIN OPHTHALMIC SOLUTION (GATIFLO® OPHTHALMIC SOLUTION 0.3%) USE-RESULT SURVEILLANCE SPECIFIED FOR NEWBORNS

  • Shinichi Maruta*1, Toshihide Suenobu*1, Ra Kin Ei*2
    *1 Senju Pharmaceutical Co., Ltd., *2 Ra Eye Clinic
  • Atarashii Ganka. 2009(10):1429-1434

POST-MARKETING SURVEILLANCE OF GATIFLOXACIN OPHTHALMIC SOLUTION (GATIFLO® 0.3% OPHTHALMIC SOLUTION) USE-RESULT SURVEILLANCE SPECIFIED FOR NEWBORNS AND INFANTS

  • Shinichi Maruta*1, Toshihide Suenobu*1, Ra Kin Ei*2
    *1 Senju Pharmaceutical Co., Ltd., *2 Ra Eye Clinic
  • Atarashii Ganka. 2007(7):975-980

POST-MARKETING SURVEILLANCE OF BROMFENAC SODIUM (BRONUCK®) OPHTHALMIC SOLUTION―Use-Results Surveillance―

  • Naoko Kitao*1, Hidemi Shimoji*1, Masahiko Fukuda*2
    *1 Senju Pharmaceutical Co.,Ltd. *2 Department of Ophthalmology, Kinki University School of Medicine
  • Atarashii Ganka. 2005(9):1299-1308

Unique action mechanism of bimatoprost, in contrast with prostaglandin F2α analogs

  • Tomoyuki Wada1、Larry A Wheeler2, David F Woodward2
    1 千寿製薬株式会社, 2 Allergan Inc.
  • Jpn J Med Pharm Sci. 2009;62:525-534.

Results of Nonclinical and Clinical Studies of TalymusR Ophthalmic Suspension 0.1% for Vernal Keratoconjunctivitis

  • Michinari Wada
  • Japanese Journal of Ocular Pharmacology Vol.23 7-10, 2009

Current Situation Regarding Prostaglandin Analogs in US

  • Takahiro Ogawa
  • Japanese Journal of Ocular Pharmacology Vol.23 73-75, 2009

| 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997